MC
HZNP

Meteora Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Meteora Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,000
Closed -$1.27M – 420
2023
Q3 		$1.27M Buy
+11,000
New +$1.18M 0.22% 111

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Meteora Capital's HZNP Position: Q4 2023 in Review

Meteora Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 11,000 shares — an estimated $1.27M sold.

Meteora Capital first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $1.27M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Meteora Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Meteora Capital sold 11,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.27M.
  • Meteora Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
  • Meteora Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.27M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Meteora Capital's 13F filing for Q4 2023, filed 14 Feb 2024.